| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667 MAWANDA ROAD | KAMPALA | | | | UGA | R21TW011554 | An implementation toolkit for the use of hydroxyurea in the treatment of sickle cell aneamia in Ugandan children | 000 | 2 | NIH | 11/12/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667 MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 001 | 5 | NIH | 2/16/2024 | $0 |
| | 2024 | 2023 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667 MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 001 | 5 | NIH | 2/16/2024 | $0 |
| | 2024 | 2022 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667 MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 000 | 4 | NIH | 2/15/2024 | $0 |
| | 2024 | 2022 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667 MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 000 | 4 | NIH | 2/15/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $521,965 ) |
| | 2023 | 2023 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 002 | 5 | NIH | 9/7/2023 | $132,434 |
| | 2023 | 2023 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 001 | 5 | NIH | 8/31/2023 | $365,031 |
| | 2023 | 2023 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 001 | 5 | NIH | 8/31/2023 | $24,500 |
| | 2023 | 2022 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 000 | 4 | NIH | 12/7/2022 | $0 |
| | 2023 | 2022 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 000 | 4 | NIH | 12/7/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $566,423 ) |
| | 2022 | 2022 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 001 | 4 | NIH | 9/2/2022 | $24,500 |
| | 2022 | 2022 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 001 | 4 | NIH | 9/2/2022 | $366,450 |
| | 2022 | 2022 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R21TW011554 | An implementation toolkit for the use of hydroxyurea in the treatment of sickle cell aneamia in Ugandan children | 000 | 2 | NIH | 6/8/2022 | $175,473 |
| | 2022 | 2021 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 000 | 3 | NIH | 5/13/2022 | $0 |
| | 2022 | 2021 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 000 | 3 | NIH | 5/13/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $571,367 ) |
| | 2021 | 2021 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R21TW011554 | An implementation toolkit for the use of hydroxyurea in the treatment of sickle cell aneamia in Ugandan children | 000 | 1 | NIH | 5/31/2021 | $185,367 |
| | 2021 | 2021 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R21TW011554 | An implementation toolkit for the use of hydroxyurea in the treatment of sickle cell aneamia in Ugandan children | 001 | 1 | NIH | 8/17/2021 | $0 |
| | 2021 | 2021 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 002 | 3 | NIH | 9/3/2021 | $361,500 |
| | 2021 | 2021 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 002 | 3 | NIH | 9/3/2021 | $24,500 |
| | 2021 | 2020 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 001 | 2 | NIH | 8/16/2021 | $0 |
| | 2021 | 2020 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 001 | 2 | NIH | 8/16/2021 | $0 |
| | 2021 | 2019 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 000 | 1 | NIH | 8/12/2021 | $0 |
| | 2021 | 2019 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 000 | 1 | NIH | 8/12/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $401,623 ) |
| | 2020 | 2020 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 001 | 2 | NIH | 9/4/2020 | $376,623 |
| | 2020 | 2020 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 001 | 2 | NIH | 9/4/2020 | $25,000 |
| | 2020 | 2019 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 000 | 1 | NIH | 10/31/2019 | $0 |
| | 2020 | 2019 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 000 | 1 | NIH | 10/31/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $464,236 ) |
| | 2019 | 2019 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 000 | 1 | NIH | 9/11/2019 | $25,000 |
| | 2019 | 2019 | GLOBAL HEALTH UGANDA LIMITED | PLOT 667, MAWANDA ROAD | KAMPALA | | | | UGA | R01HD096559 | Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II) | 000 | 1 | NIH | 9/11/2019 | $439,236 |
|
|
